Viive M. Howell

A molecular diagnosis of hyperparathyroidism-jaw tumor syndrome in an adolescent with recurrent kidney stones.

Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype.

Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.

Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism.

Evidence for a direct role of the disease modifier SCNM1 in splicing.

A targeted deleterious allele of the splicing factor SCNM1 in the mouse.

Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.

CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.

The use of denaturing high performance liquid chromatography (DHPLC) for mutation scanning of hereditary cancer genes.

Sleeping beauty--a mouse model for all cancers?

Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.

Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer.

Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes.

Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia.

Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy.

Genetically engineered mouse models for epithelial ovarian cancer: are we there yet?

Mice and men working together for over 100 years in the fight against cancer.

From mice to men: GEMMs as trial patients for new NSCLC therapies.

Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines.

Genetically engineered insertional mutagenesis in mice to model cancer: Sleeping Beauty.

Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma.

Genomic alterations as mediators of miRNA dysregulation in ovarian cancer.

Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines.

Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.